FierceBiotechOriginal article
{"a":[{"_":"Axoltis misses the mark in phase 2 ALS study, but will persevere with the synthetic peptide","$":{"href":"/biotech/axoltis-misses-mark-phase-2-als-study-still-strives-move-towards-clinic","hreflang":"en"}}]}
Phase 2negativeNegative
AI Analysis
Summary
Axoltis Pharma's phase 2 trial of a synthetic peptide for amyotrophic lateral sclerosis missed its primary endpoint, but the company plans to continue development citing positive secondary endpoints.
Clinical Trial Data
Phase
2
Primary Endpoint
Not Met
Outcome Details
Missed primary endpoint in phase 2 ALS trial; secondary endpoints cited as justification to continue development
Importance:6/10
Sentiment:
-0.30
Phase 2ALSClinical TrialNegative ResultsDrug Development
Read the original article
Published by FierceBiotech on September 14, 2026 11:16 AM